ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer
RF Morton, EH Hammond - Journal of Oncology Practice, 2009 - ascopubs.org
RF Morton, EH Hammond
Journal of Oncology Practice, 2009•ascopubs.orgASCO's Provisional Clinical Opinion alerts oncologists to emerging information from recent
clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab
and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus,
patients with colorectal cancer with these mutations should be spared the toxicity and cost of
an ineffective therapy.
clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab
and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus,
patients with colorectal cancer with these mutations should be spared the toxicity and cost of
an ineffective therapy.
ASCO's Provisional Clinical Opinion alerts oncologists to emerging information from recent clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus, patients with colorectal cancer with these mutations should be spared the toxicity and cost of an ineffective therapy.
ASCO Publications